It certainly might concern Arovella Therapeutics Limited ( ASX:ALA ) shareholders to see the share price down 31% in...
Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance with Arovella Therapeutics Ltd (ASX: ALA). This collaboration emphasizes the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-iNKT cell therapy.